[1]岳楚慧 袁素军.肥厚心肌病的靶向药物研究进展[J].心血管病学进展,2025,(11):1000.[doi:10.16806/j.cnki.issn.1004-3934.2025.11.009]
　YUE chuhui,YUAN sujun.Targeted drugs for Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2025,(11):1000.[doi:10.16806/j.cnki.issn.1004-3934.2025.11.009]
点击复制

肥厚心肌病的靶向药物研究进展()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年11期
页码:
1000
栏目:
综述
出版日期:
2025-11-25

文章信息/Info

Title:
Targeted drugs for Hypertrophic Cardiomyopathy
作者:
岳楚慧 袁素军
(山西医科大学第二医院心血管内科,山西 太原 030009)
Author(s):
YUE chuhui; YUAN sujun
(Department of Cardiology， The Second Hospital of Shanxi Medical University，Taiyuan 030009，Shanxi，China)
关键词:
肥厚心肌病; 遗传机制; 靶向药物
Keywords:
Hypertrophic cardiomyopathy;  Genetic mechanism;  Targeted drugs
DOI:
10.16806/j.cnki.issn.1004-3934.2025.11.009
摘要:
肥厚心肌病的药物治疗正从传统模式向精准靶向治疗转。传统药物如β受体阻滞剂、非二氢吡啶类钙通道阻滞剂虽可降心肌耗氧量，但存在疗效局限。以肌球蛋白抑制剂mavacamten为代表的新靶向药物，通过特异性抑制心肌过度收缩显著改善左室流出道梗阻，为症状性肥厚型心肌病提供突破性治疗选择，但其对能的潜在抑制仍需动态监测。对肥厚心肌病的靶向药物研究进展进行综述，以期为基础和临床研究提供思路。
Abstract:
Precision targeted therapy is replacing traditional pharmacological treatment for hypertrophic cardiomyopathy. Traditional medications including β-blockers and non-dihydropyridine calcium channel blockers can lower myocardial oxygen demand,but their effectiveness is limited. By specifically blocking myocardial hypercontraction,the new targeted medications,exemplified by the myosin inhibitor mavacamten,greatly reduce left ventricular outflow tract obstruction and offered a revolutionary treatment option for symptomatic hypertrophic cardiomyopathy. However,its potential to impair left ventricular systolic function still requires dynamic monitoring. Therefore,in order to generate ideas for basic and clinical research,this paper examines the research development of targeted medications in hypertrophic cardiomyopathy.

参考文献/References:

[1].Omen SR,Ho CY,Asif IM,et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy:a report of the American heart association/american college of cardiology joint committee on clinical practice guidelines[J]. Circulation,2024,149(23):1239-1311.
[2].Nguyen MB,Mital S,Mertens L,et al. Pediatric hypertrophic cardiomyopathy:exploring the genotype-phenotype association[J]. JAMA,2022,11(5):e024220.
[3].Semsarian C,Ingles J,Maron MS,et al. New perspectives on the prevalence of hypertrophic cardiomyopathy[J]. J Am Coll Cardiol,2015,65(12):1249-1254.
[4].Arbelo E,Protonotarios A,Gimeno JR,et al. 2023 ESC guidelines for the management of cardiomyopathies[J]. Eur Heart J,2023,44(37):3503-3626.
[5].Spudich JA,Nandwani N,Robert-Paganin J,et al. Reassessing the unifying hypothesis for hypercontractility caused by myosin mutations in hypertrophic cardiomyopathy[J]. EMBO J,2024,43(19):4139-4155.
[6].Barrick SK,Greenberg MJ. Cardiac myosin contraction and mechanotransduction in health and disease[J]. J Biol Chem,2021,297(5):101297.
[7].Chen J,Xing Y,Sun J,et al. Hypertrophic cardiomyopathy:genes and mechanisms[J]. Front Biosci (Landmark Ed),2025,30(2):25714.
[8].Tudurachi BS,Z?voi A,Leonte A,et al. An update on MYBPC3 gene mutation in hypertrophic cardiomyopathy[J]. Int J Mol Sci,2023,24(13):10510.
[9].Hamstra SI,Whitley KC,Baranowski RW,et al. The role of phospholamban and GSK3 in regulating rodent cardiac SERCA function[J]. Am J Physiol Cell Physiol Cell Physiology,2020,319(4):C694-C699.
[10].Olalekan SO,Bakare OO,Okwute PG,et al. Hypertrophic cardiomyopathy:Insights into pathophysiology and novel therapeutic strategies from clinical studies[J]. Egypt Heart J,2025,77:5.
[11].Wang Q,Michalak M. Calsequestrin. Structure,function,and evolution[J]. Cell Calcium,2020,90:102242.
[12].Lv T,Li S,Li Q,et al. The role of RyR2 mutations in congenital heart diseases:insights into cardiac electrophysiological mechanisms[J]. J Cardiovasc Electrophysiol,2025,36(3):683-692.
[13].Matuz-Mares D,González-Andrade M,Araiza-Villanueva MG,et al. Mitochondrial calcium:effects of its imbalance in disease[J]. Antioxidants (Basel),2022,11(5):801.
[14].Sun Z,Wang L,Han L,et al. Functional calsequestrin-1 is expressed in the heart and its deficiency is causally related to malignant hyperthermia-like arrhythmia[J]. Circulation,2021,144(10):788-804.
[15].Shimada YJ,Ratita Y,Liang LW,et al. Comprehensive proteomics profiling reveals circulating biomarkers of hypertrophic cardiomyopathy[J]. Circ Heart Fail,2021,14(7):e007849.
[16].Hu HH,Chen DQ,Wang YN,et al. New insights into TGF-β/smad signaling in tissue fibrosis[J]. Chem Biol Interact,2018,292:76-83.
[17].Livingston MJ,Zhang M,Kwon SH,et al. Autophagy activates EGR1 via MAPK/ERK to induce FGF2 in renal tubular cells for fibroblast activation and fibrosis during maladaptive kidney repair[J]. Autophagy,2024,20(5):1032-1053.
[18].Maron MS,Rowin EJ,Wessler BS,et al. Enhanced American college of cardiology/american heart association strategy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy[J]. JAMA cardiol,2019,4(7):644-657.
[19].Frangogiannis NG. Transforming growth factor-β in myocardial disease[J]. Nat Rev Cardiol,2022,19(7):435-455.
[20].Pelliccia F,Cecchi F,Olivotto I,et al. Microvascular dysfunction in hypertrophic cardiomyopathy[J]. J Clin Med,2022,11(21):6560.
[21].Wijnker PJM,Van Der Velden J. Mutation-specific pathology and treatment of hypertrophic cardiomyopathy in patients,mouse models and human engineered heart tissue[J]. Biochim Biophys Acta Mol Basis Dis,2020,1866(8):165774.
[22].Bogomolovas J,Chen J. A therapeutic leap:how myosin inhibitors moved from cardiac interventions to skeletal muscle myopathy solutions[J]. J Clin Invest,2024,134(9):e179958.
[23].Zatorski N,Sobie EA,Schlessinger A. Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients[J]. Trends Pharmacol Sci,2023,44(5):318-319.
[24].Olivotto I,Oreziak A,Barriales-Villa R,et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM):a randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet,2020,396(10253):759-769.
[25].Cremer PC,Geske JB,Owens A,et al. Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy:Insights from the VALOR-HCM study[J]. Circ Cardiovasc Imaging,2022,15(12):e014986.
[26].Day SM,Udelson JE,Bonow RO. Long-term efficacy and safety of mavacamten in symptomatic patients with obstructive hypertrophic cardiomyopathy[J]. JAMA Cardiol,2023,8(10):978.?
[27].Tian Z,Li L,Li X,et al. Effect of Mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy:the EXPLORER-CN randomized clinical trial[J]. JAMA Cardiology,2023,8(10):957-965.
[28].Kitaoka H,Ieda M,Ebato M,et al. Phase 3 open-label study evaluating the efficacy and safety of mavacamten in japanese adults with obstructive hypertrophic cardiomyopathy—The HORIZON-HCM study[J]. Circ J,2024,89(1):130-138.
[29].中国成人肥厚心肌病诊断治疗指南2023[J]. 中国分子心脏病学杂志,2023,23(1):5115-5149.
[30].Maron MSMasri A,Nassif ME,et al. Aficamten for symptomatic obstructive hypertrophic cardiomyopathy[J]. N Engl J Med,2024,390(20):1849-1861.
[31].Maron MS,Masri A,Choudhury L,et al. Phase 2 study of aficamten in patients?with obstructive hypertrophic?cardiomyopathy[J]. J Am Coll Cardiol,2023,81(1):34-45.
[32].Masri A,Choudhury L,Barriales-Villa R,et al. Standard-of-care medication withdrawal in patients with obstructive hypertrophic cardiomyopathy receiving aficamten in FOREST-HCM[J]. J Am Coll Cardiol,2024,84(19):1839-1849.
[33].Masri A,Barriales-Villa R,Elliott P,et al. Safety and efficacy of aficamten in patients with non-obstructive hypertrophic cardiomyopathy:a 36-week analysis from FOREST-HCM[J]. Eur J Heart Fail,2024,26(9):1993-1998.
[34].Coats CJ,Masri A,Barriales-Villa R,et al. Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy:The SEQUOIA-HCM trial[J]. Eur Heart J,2024,45(42):4464-4478.
[35].Dybro AM,Rasmussen TB,Nielsen RR,et al. Metoprolol improves left ventricular longitudinal strain at rest and during exercise in obstructive hypertrophic cardiomyopathy[J]. J Am Soc Echocardiogr,2023,36(2):196-204.
[36].Bayonas-Ruiz A,Munoz-Franco FM,Sabater-Molina M,et al. Current therapies for hypertrophic cardiomyopathy:a systematic review and meta-analysis of the literature[J]. ESC Heart Fail,2023,10(1):8-23.
[37].Maurizi N,Chiriatti C,Fumagalli C,et al. Real-world use and predictors of response to disopyramide in patients with obstructive hypertrophic cardiomyopathy[J]. J Clin Med,2023,12(7):2725.
[38].Olivotto I,Camici PG,Merlini PA,et al. Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy:the RESTYLE-HCM randomized,double-blind,placebo-controlled study[J]. Circ Heart Fail,2018,11(1):e004124.
[39].Ho CY,Day SM,Axelsson A,et al. Valsartan in early-stage hypertrophic cardiomyopathy:a randomized phase 2 trial[J]. Nat Med,2021,27(10):1818-1824.
[40].Zhang J,He X,Bai X,et al.Protective effect of trimetazidine in radiation-induced cardiac fibrosis in mice[J]. J Radiat Res,2020,61(5):657-665.?
[41].Greer-Short A,Greenwood A,Leon EC,et al. AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models[J]. Nat Commun,2025,16:2196.
[42].Chai AC,Cui M,Chemello F,et al. Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes and humanized mice[J]. Nat Med,2023,29(2):401-411.
[43].Shen A,Chen D,Kaur M,et al. β-blockers augment L-type Ca2+ channel activity by targeting spatially restricted β2AR signaling in neurons[J]. Elife,2019,8:e49464.
[44].Li W,Shi G. How CaV1.2-bound verapamil blocks Ca2+ influx into cardiomyocyte:Atomic level views[J]. Pharmacol Res,2019,139:153-157.
[45].Maning J,Desimine VL,Pollard CM,et al. Carvedilol selectively stimulates βarrestin2-dependent SERCA2a activity in cardiomyocytes to augment contractility[J]. Int J Mol Sci,2022,23(19):11315.
[46].Vissing CR,Axelsson Raja A,Day SM,et al. Cardiac remodeling in subclinical hypertrophic cardiomyopathy:the VANISH randomized clinical trial[J]. JAMA Cardiol,2023,8(11):1083 1088.
[47].Argiro A,Bui Q,Hong KN,et al. Applications of gene therapy in?cardiomyopathies[J]. JACC Heart Fail,2024,12(2):248-260.
[48].Repetti GG,Toepfer CN,Seidman JG,et al. Novel therapies for prevention and early treatment of cardiomyopathies[J]. Circu Res,2019,124(11):1536-1550.
[49].Paratz ED,Mundisugih J,Rowe SJ,et al. Gene therapy in cardiology:is a cure for hypertrophic cardiomyopathy on the horizon?[J]. Can J Cardiol,2024,40(5):777-788.?
[50].Dainis A,Zaleta-Rivera K,Ribeiro A,et al. Silencing of MYH7 ameliorates disease phenotypes in human iPSCcardiomyocytes[J]. Physiol Genomics,2020,52(7):293-303.

相似文献/References:

[1]谭莹 易龙 谢峻 徐标 陆剑嵘.一个家族肥厚心肌病的遗传学分析[J].心血管病学进展,2020,(8):880.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.023]
　TAN Ying,YI Long,XIE Jun,et al.Genetic Analysis of A Familial Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2020,(11):880.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.023]
[2]刘珊珊,王岳恒,赵卉霖.肥厚心肌病动态梗阻的研究进展[J].心血管病学进展,2021,(6):508.[doi:10.16806/j.cnki.issn.1004-3934.20.06.008]
　LIU Shanshan,WANG Yueheng,ZHAO Huilin.Dynamic Obstruction in Hypertrophic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(11):508.[doi:10.16806/j.cnki.issn.1004-3934.20.06.008]

更新日期/Last Update: 2026-03-06